Cargando…

Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength

We have examined the effects of intravenous (IV) delivery of rAAVrh74.MHCK7.GALGT2 in the golden retriever muscular dystrophy (GRMD) model of Duchenne Muscular Dystrophy (DMD). After baseline testing, GRMD dogs were treated at 3 months of age and reassessed at 6 months. This 3–6 month age range is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Paul T., Zygmunt, Deborah A., Ashbrook, Anna, Hamilton, Sonia, Packer, Davin, Birch, Sharla M., Bettis, Amanda K., Balog-Alvarez, Cynthia J., Guo, Lee-Jae, Nghiem, Peter P., Kornegay, Joe N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997012/
https://www.ncbi.nlm.nih.gov/pubmed/33770101
http://dx.doi.org/10.1371/journal.pone.0248721
_version_ 1783670230893985792
author Martin, Paul T.
Zygmunt, Deborah A.
Ashbrook, Anna
Hamilton, Sonia
Packer, Davin
Birch, Sharla M.
Bettis, Amanda K.
Balog-Alvarez, Cynthia J.
Guo, Lee-Jae
Nghiem, Peter P.
Kornegay, Joe N.
author_facet Martin, Paul T.
Zygmunt, Deborah A.
Ashbrook, Anna
Hamilton, Sonia
Packer, Davin
Birch, Sharla M.
Bettis, Amanda K.
Balog-Alvarez, Cynthia J.
Guo, Lee-Jae
Nghiem, Peter P.
Kornegay, Joe N.
author_sort Martin, Paul T.
collection PubMed
description We have examined the effects of intravenous (IV) delivery of rAAVrh74.MHCK7.GALGT2 in the golden retriever muscular dystrophy (GRMD) model of Duchenne Muscular Dystrophy (DMD). After baseline testing, GRMD dogs were treated at 3 months of age and reassessed at 6 months. This 3–6 month age range is a period of rapid disease progression, thus offering a relatively short window to establish treatment efficacy. Measures analyzed included muscle AAV transduction, GALGT2 transgene expression, GALGT2-induced glycosylation, muscle pathology, and muscle function. A total of five dogs were treated, 4 at 2x10(14)vg/kg and one at 6x10(14)vgkg. The 2x10(14)vg/kg dose led to transduction of regions of the heart with 1–3 vector genomes (vg) per nucleus, while most skeletal muscles were transduced with 0.25–0.5vg/nucleus. GALGT2-induced glycosylation paralleled levels of myofiber vg transduction, with about 90% of cardiomyocytes having increased glycosylation versus 20–35% of all myofibers across the skeletal muscles tested. Conclusions from phenotypic testing were limited by the small number of dogs. Treated dogs had less pronounced fibrosis and overall lesion severity when compared to control groups, but surprisingly no significant changes in limb muscle function measures. GALGT2-treated skeletal muscle and heart had elevated levels of utrophin protein expression and GALGT2-induced expression of glycosylated α dystroglycan, providing further evidence of a treatment effect. Serum chemistry, hematology, and cardiac function measures were largely unchanged by treatment. Cumulatively, these data show that short-term intravenous treatment of GRMD dogs with rAAVrh74.MHCK7.GALGT2 at high doses can induce muscle glycosylation and utrophin expression and may be safe over a short 3-month interval, but that such treatments had only modest effects on muscle pathology and did not significantly improve muscle strength.
format Online
Article
Text
id pubmed-7997012
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-79970122021-04-06 Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength Martin, Paul T. Zygmunt, Deborah A. Ashbrook, Anna Hamilton, Sonia Packer, Davin Birch, Sharla M. Bettis, Amanda K. Balog-Alvarez, Cynthia J. Guo, Lee-Jae Nghiem, Peter P. Kornegay, Joe N. PLoS One Research Article We have examined the effects of intravenous (IV) delivery of rAAVrh74.MHCK7.GALGT2 in the golden retriever muscular dystrophy (GRMD) model of Duchenne Muscular Dystrophy (DMD). After baseline testing, GRMD dogs were treated at 3 months of age and reassessed at 6 months. This 3–6 month age range is a period of rapid disease progression, thus offering a relatively short window to establish treatment efficacy. Measures analyzed included muscle AAV transduction, GALGT2 transgene expression, GALGT2-induced glycosylation, muscle pathology, and muscle function. A total of five dogs were treated, 4 at 2x10(14)vg/kg and one at 6x10(14)vgkg. The 2x10(14)vg/kg dose led to transduction of regions of the heart with 1–3 vector genomes (vg) per nucleus, while most skeletal muscles were transduced with 0.25–0.5vg/nucleus. GALGT2-induced glycosylation paralleled levels of myofiber vg transduction, with about 90% of cardiomyocytes having increased glycosylation versus 20–35% of all myofibers across the skeletal muscles tested. Conclusions from phenotypic testing were limited by the small number of dogs. Treated dogs had less pronounced fibrosis and overall lesion severity when compared to control groups, but surprisingly no significant changes in limb muscle function measures. GALGT2-treated skeletal muscle and heart had elevated levels of utrophin protein expression and GALGT2-induced expression of glycosylated α dystroglycan, providing further evidence of a treatment effect. Serum chemistry, hematology, and cardiac function measures were largely unchanged by treatment. Cumulatively, these data show that short-term intravenous treatment of GRMD dogs with rAAVrh74.MHCK7.GALGT2 at high doses can induce muscle glycosylation and utrophin expression and may be safe over a short 3-month interval, but that such treatments had only modest effects on muscle pathology and did not significantly improve muscle strength. Public Library of Science 2021-03-26 /pmc/articles/PMC7997012/ /pubmed/33770101 http://dx.doi.org/10.1371/journal.pone.0248721 Text en © 2021 Martin et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Martin, Paul T.
Zygmunt, Deborah A.
Ashbrook, Anna
Hamilton, Sonia
Packer, Davin
Birch, Sharla M.
Bettis, Amanda K.
Balog-Alvarez, Cynthia J.
Guo, Lee-Jae
Nghiem, Peter P.
Kornegay, Joe N.
Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength
title Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength
title_full Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength
title_fullStr Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength
title_full_unstemmed Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength
title_short Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength
title_sort short-term treatment of golden retriever muscular dystrophy (grmd) dogs with raavrh74.mhck7.galgt2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997012/
https://www.ncbi.nlm.nih.gov/pubmed/33770101
http://dx.doi.org/10.1371/journal.pone.0248721
work_keys_str_mv AT martinpault shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength
AT zygmuntdeboraha shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength
AT ashbrookanna shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength
AT hamiltonsonia shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength
AT packerdavin shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength
AT birchsharlam shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength
AT bettisamandak shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength
AT balogalvarezcynthiaj shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength
AT guoleejae shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength
AT nghiempeterp shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength
AT kornegayjoen shorttermtreatmentofgoldenretrievermusculardystrophygrmddogswithraavrh74mhck7galgt2inducesmuscleglycosylationandutrophinexpressionbuthasnosignificanteffectonmusclestrength